检索结果-南通市图书馆

国际医学放射学杂志 2011年第4期 384-385页

作者： j.a.talwalkar K.j.Glaser S.O.Sanderson R.L.Ehman 马可云 Department of Radiology Mayo Clinic

目的探讨MR弹性成像对发现早期非酒精性脂肪性肝病(NAFLD)中的非酒精性脂肪性肝炎(NASH)的诊断准确性[受试者操作特征曲线下面积(AUROC)]。材料与方法符合HIPAA并无需病人知情同意,回顾分析了58例NAFLD

关键词：非酒精性脂肪性肝病人 NAFLD 炎症病理肝硬度弹性成像 MR

MR弹性成像无创性评估非酒精性脂肪肝进行性肝纤维化

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

国际医学放射学杂志 2013年第5期 480-480页

作者： D.Kim W.R.Kim j.a.talwalkar H.j.Kim R.L.Ehman 王影 Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine

摘要目的评价MR弹性成像辅助诊断临床非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)大量纤维化的准确性,以MR弹性成像为参考标准,比较各种实验室指标鉴别NAFLD和进行性纤维化的价值。材料与方法本回顾性研究获得伦理委... 详细信息

摘要目的评价MR弹性成像辅助诊断临床非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)大量纤维化的准确性,以MR弹性成像为参考标准,比较各种实验室指标鉴别NAFLD和进行性纤维化的价值。材料与方法本回顾性研究获得伦理委员会的批准,免除签署知情同意书。研究对象的纳入标准为一组前瞻性影像诊断NAFLD的病人中接受MR弹性成像者。以活检结果为准,比较基于实验室检查结果诊断纤维化的指标与弹性成像结果。比较每一项数据的ROC曲线下面积(AUROC)、敏感度、特异度、阳性预测值、阴性预测值。结果行MR弹性成像的NAFLD病人共

关键词：弹性成像病人 NAFLD 进行性 MR 肝纤维化肝疾病

肝脏MR弹性成像:一组1377例序贯性检查的临床表现

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

国际医学放射学杂志 2016年第2期 181-181页

作者： M.Yin K.j.Glaser j.a.talwalkar j.Chen A.Manduca R.L.Ehman 罗宁 Department of Radiology Mayo Clinic

摘要目的评估肝脏MR弹性成像技术的成功率与诊断价值。材料与方法该回顾性研究经机构伦理委员会批准,并且获得病人知情同意。在2007—2010年间,共进行了1 377

关键词：弹性成像成功率 MR 肝脏

MR弹性成像和振动控制瞬时弹性成像对重度到病态肥胖病人肝纤维化的诊断性能

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

国际医学放射学杂志 2017年第4期 462-462页

作者： j.Chen M.Yin j.a.talwalkar j.Oudry K.j.Glaser T.C.Smyrk 刘学焕 Department of Radiology Mayo Clinic

摘要目的评价MR弹性成像和振动控制瞬时弹性成像(VCTE)对重度到病态肥胖病人肝纤维化诊断性能和检查成功率。材料与方法本项前瞻性研究符合HIPAA并经机构伦理委员会批准。共招募111例病人(女71例,男40例),所有病人均签署知情同意书。病...

摘要目的评价MR弹性成像和振动控制瞬时弹性成像(VCTE)对重度到病态肥胖病人肝纤维化诊断性能和检查成功率。材料与方法本项前瞻性研究符合HIPAA并经机构伦理委员会批准。共招募111例病人(女71例,男40例),所有病人均签署知情同意书。病人MR弹性成像及VCTE分别由2名和3名阅片者获取用于评估肝纤维化的肝硬化指标,并与肝活检结果进行比较。每份病理标本均由2名肝脏病理

关键词：

吗替麦考酚酯在熊脱氧胆酸不敏感的原发性胆汁性肝硬化患者中的治疗作用

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（胃肠病学分册） 2005年第6期1卷 53-54页

作者： talwalkar j.A. Angulo P. Keach j.C. 王铮 Div. of Gastroenterol. and Hepatol. Mayo Clinic and Foundation 200 First Street SW RochesterMN55905 United States Dr.

Background&Aims: Despite evidence for therapeutic efficacy with ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC), only 30-50%of patients achieve complete biochemical remission within 1 year of therapy. Mycophenolate mofetil (MMF) is an immunosuppressive medication that inhibits T and B lymphocyte proliferation. The aim of this investigation was to determine the safety and estimated efficacy of MMF in patients with PBC. Methods: Twenty-five patients with incomplete responses to UDCA (defined as persistent elevation of serum alkaline phosphatase ≥2 times the upper limit of normal) received MMF 1 g daily to a maximum of 3 g daily with UDCA (13-15 mg/kg per day) for 1 year. Liver biochemistries were determined at 3-month intervals with Mayo Risk Score calculated at baseline and end of therapy. Results: Nineteen (76%) patients completed 1 year of therapy. Despite improvements in serum alkaline phosphatase (920 ±308 vs. 709 ±242 IU/L, P = 0.001) and AST (65 ±31 vs. 51 ±19 IU/L, P = 0.007) levels, these findings were clinically insignificant. Exploratory analysis revealed a strong correlation between advanced PBC defined by higher Mayo Risk Score and reduction in serum alkaline phosphatase levels (r = -0.74, P = 0.006). Six patients (24%) did not complete therapy; adverse drug events were responsible for study withdrawal in 3 individuals. Adverse reactions that resolved spontaneously or by dose reduction occurred in 13 patients. Conclusions: MMF is not associated with important clinical benefits in PBC based on the results of this pilot investigation.

关键词：吗替麦考酚酯治疗作用熊脱氧胆酸正常值上限血清碱性磷酸酶免疫抑制剂中评估生化指标

维普期刊数据库

Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment

在线全文

学校读者我要写书评

暂无评论

Open journal of Rheumatology and Autoimmune Diseases 2012年第2期2卷 6-13页

作者： Deana D. Hoganson jun Chen Richard L. Ehman jayant A. talwalkar Clement j. Michet Meng Yin Cynthia S. Crowson Eric L. Matteson Department of Gas-troenterology and Hepatology Mayo Clinic Rochester MN Department of Health Sciences Research Mayo Clinic Rochester MN Department of Radiology Mayo Clinic Rochester MN Division of Rheumatology Mayo Clinic Rochester Division of Rheumatology Mayo Clinic Rochester

Introduction: Hepatic magnetic resonance elastography (MRE) allows for noninvasive assessment of liver fibrosis. The purpose of this study was to evaluate the usefulness of MRE in detecting and quantifying liver fibrosis in patients with rheumatoid arthritis (RA) who have received methotrexate (MTX). Methods: The association between mean liver stiffness value as determined by MRE and variables of interest was determined. The decision for a liver biopsy in participants with an abnormal liver stiffness was made based on clinical judgment. Results: Sixty-five RA patients were enrolled. Mean liver stiffness value by MRE was abnormal in 7 patients, suggestive of hepatic injury. As a result of findings from the MRE, biopsies were performed in 5 patients and all correlated with elevated liver stiffness values. Elevated mean liver stiffness values were associated with body mass index (BMI) (OR = 1.18 per 1 kg/m2;95% CI: 1.03, 1.36;p = 0.017). Neither the total MTX dose nor the duration of MTX treatment was associated with mean liver stiffness value (p = 0.51 and P = 0.20, respectively). Conclusion: MRE provides a reliable, non-invasive assessment of liver fibrosis in patients with RA receiving MTX. Patients with RA receiving MTX who have an elevated BMI may be at increased risk for chronic hepatic injury, regardless of MTX cumulative dose or duration of treatment.

关键词： Methotrexate Hepatic Magnetic Resonance Elastography Liver Fibrosis Rheumatoid Arthritis